Physician profile
Danielle Corbett
NPI 1700450715
$764.63
in general payments reported to CMS, 2019-2025
14 companies · $534 in 2025
The $534 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $231 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $322.86 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.71 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $79.68 | 2024-2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.31 | 2025 | Caplyta |
| Abbvie INC. | $37.73 | 2025 | |
| Pfizer INC. | $32.67 | 2024-2025 | |
| Bioventus LLC | $25.68 | 2025 | Exogen Ultrasound Bone Healing System |
| Vanda Pharmaceuticals INC. | $25.37 | 2025 | Fanapt |
| Dexcom, INC. | $25.26 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $19.65 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $18.81 | 2025 | Rexulti |
| Tactile Systems Technology INC | $17.57 | 2025 | Nimbl, Flexitouch Plus |
| Lilly USA, LLC | $16.90 | 2024 | Mounjaro, Zepbound |
| Lundbeck LLC | $15.43 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Corbett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.